PMID- 24796339
OWN - NLM
STAT- MEDLINE
DCOM- 20150616
LR  - 20151119
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Linking)
VI  - 35
IP  - 37
DP  - 2014 Oct 1
TI  - Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary 
      percutaneous coronary intervention for acute anterior ST-segment elevation 
      myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial.
PG  - 2516-23
LID - 10.1093/eurheartj/ehu177 [doi]
AB  - AIMS: Delcasertib is a selective inhibitor of delta-protein kinase C (delta-PKC), 
      which reduced infarct size during ischaemia/reperfusion in animal models and 
      diminished myocardial necrosis and improved reperfusion in a pilot study during 
      primary percutaneous coronary intervention (PCI) for ST elevation myocardial 
      infarction (STEMI). METHODS AND RESULTS: A multicentre, double-blind trial was 
      performed in patients presenting within 6 h and undergoing primary PCI for 
      anterior (the primary analysis cohort, n = 1010 patients) or inferior (an 
      exploratory cohort, capped at 166 patients) STEMI. Patients with anterior STEMI 
      were randomized to placebo or one of three doses of delcasertib (50, 150, or 450 
      mg/h) by intravenous infusion initiated before PCI and continued for  approximately 2.5 h. 
      There were no differences between treatment groups in the primary efficacy 
      endpoint of infarct size measured by creatine kinase MB fraction area under the 
      curve (AUC) (median 5156, 5043, 4419, and 5253 ng h/mL in the placebo, 
      delcasertib 50, 150, and 450 mg/mL groups, respectively) in the anterior STEMI 
      cohort. No treatment-related differences were seen in secondary endpoints of 
      infarct size, electrocardiographic ST-segment recovery AUC or time to stable ST 
      recovery, or left ventricular ejection fraction at 3 months. No differences in 
      rates of adjudicated clinical endpoints (death, heart failure, or serious 
      ventricular arrhythmias) were observed. CONCLUSIONS: Selective inhibition of 
      delta-PKC with intravenous infusion of delcasertib during PCI for acute STEMI in 
      a population of patients treated according to contemporary standard of care did 
      not reduce biomarkers of myocardial injury.
CI  - Published on behalf of the European Society of Cardiology. All rights reserved. (c) 
      The Author 2014. For permissions please email: journals.permissions@oup.com.
FAU - Lincoff, A Michael
AU  - Lincoff AM
AD  - Cleveland Clinic Coordinating Center for Clinical Research (C5Research), 
      Cleveland, OH, USA lincofa@ccf.org.
FAU - Roe, Matthew
AU  - Roe M
AD  - Duke Clinical Research Institute, Durham, NC, USA.
FAU - Aylward, Philip
AU  - Aylward P
AD  - Flinders University and Medical Centre, Adelaide, Australia.
FAU - Galla, John
AU  - Galla J
AD  - Cleveland Clinic Coordinating Center for Clinical Research (C5Research), 
      Cleveland, OH, USA.
FAU - Rynkiewicz, Andrzej
AU  - Rynkiewicz A
AD  - Department of Cardiology and Cardiosurgery, University of Warmia and Mazury, 
      Olsztyn, Poland.
FAU - Guetta, Victor
AU  - Guetta V
AD  - Heart Institute, Sheba Medical Center, Tel Hashomer, Israel.
FAU - Zelizko, Michael
AU  - Zelizko M
AD  - Department of Cardiology, Institute for Clinical and Experimental Medicine, 
      Prague, Czech Republic.
FAU - Kleiman, Neal
AU  - Kleiman N
AD  - Methodist DeBakey Heart & Vascular Center, Houston, TX, USA.
FAU - White, Harvey
AU  - White H
AD  - Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand.
FAU - McErlean, Ellen
AU  - McErlean E
AD  - Cleveland Clinic Coordinating Center for Clinical Research (C5Research), 
      Cleveland, OH, USA.
FAU - Erlinge, David
AU  - Erlinge D
AD  - Department of Cardiology, Lund University, Lund, Sweden.
FAU - Laine, Mika
AU  - Laine M
AD  - Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland.
FAU - Dos Santos Ferreira, Jorge Manuel
AU  - Dos Santos Ferreira JM
AD  - Department of Cardiology, Hospital Santa Cruz, Carnaxide, Portugal.
FAU - Goodman, Shaun
AU  - Goodman S
AD  - Canadian Heart Research Centre and St. Michael's HospitalUniversity of Toronto, 
      Toronto, Ontario, Canada.
FAU - Mehta, Shamir
AU  - Mehta S
AD  - Department of Cardiology, Hamilton General Hospital Hamilton, Ontario, Canada.
FAU - Atar, Dan
AU  - Atar D
AD  - Department of Cardiology B, Oslo University Hospital, Norway, and Institute of 
      Clinical Sciences, University of Oslo, Oslo, Norway.
FAU - Suryapranata, Harry
AU  - Suryapranata H
AD  - Department of Cardiology, Radboud University Nijmegen Medical Center, The 
      Netherlands.
FAU - Jensen, Svend Eggert
AU  - Jensen SE
AD  - Department of Cardiology, Arhus University Hospital, Aalborg, Denmark.
FAU - Forster, Tamas
AU  - Forster T
AD  - Medical Faculty, University of Szeged and Albert Szent-Gyorgyi Medical and 
      Pharmaceutical Center, Szeged, Hungary.
FAU - Fernandez-Ortiz, Antonio
AU  - Fernandez-Ortiz A
AD  - Coronary Care Unit, Hospital Clinico San Carlos, Madrid, Spain.
FAU - Schoors, Danny
AU  - Schoors D
AD  - Interventional Department, Universitair Ziekenhuis Brussel, Belgium.
FAU - Radke, Peter
AU  - Radke P
AD  - Department of Cardiology, Angiology, Intensive Care Medicine, University of 
      Schleswig Holstein, Lubeck, Germany.
FAU - Belli, Guido
AU  - Belli G
AD  - Unita Operativa di Emodinamica e Cardiologia Invasiva Istitutio Clinico 
      Humanitas, Milano, Italy.
FAU - Brennan, Danielle
AU  - Brennan D
AD  - Cleveland Clinic Coordinating Center for Clinical Research (C5Research), 
      Cleveland, OH, USA.
FAU - Bell, Gregory
AU  - Bell G
AD  - KAI Phamaceuticals and Department of Medicine, University of California San 
      Francisco, San Francisco, CA, USA.
FAU - Krucoff, Mitchell
AU  - Krucoff M
AD  - Duke Clinical Research Institute, Durham, NC, USA.
CN  - PROTECTION AMI Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00785954
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140505
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Biomarkers)
RN  - 0 (KAI 9803)
RN  - 0 (Peptides)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Troponin I)
RN  - EC 2.7.3.2 (Creatine Kinase, MB Form)
SB  - IM
CIN - Eur Heart J. 2014 Oct 1;35(37):2504-6. PMID: 24875796
MH  - Aged
MH  - Area Under Curve
MH  - Biomarkers/metabolism
MH  - Chemotherapy, Adjuvant
MH  - Creatine Kinase, MB Form/metabolism
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*therapy
MH  - Peptides/*administration & dosage
MH  - Percutaneous Coronary Intervention/*methods
MH  - Pilot Projects
MH  - Protein Kinase Inhibitors/*administration & dosage
MH  - Treatment Outcome
MH  - Troponin I/metabolism
OTO - NOTNLM
OT  - Myocardial
OT  - Myocardial infarction
OT  - Pharmacology
OT  - Reperfusion
OT  - Stents
OT  - Stunning
EDAT- 2014/05/07 06:00
MHDA- 2015/06/17 06:00
CRDT- 2014/05/07 06:00
PHST- 2014/05/07 06:00 [entrez]
PHST- 2014/05/07 06:00 [pubmed]
PHST- 2015/06/17 06:00 [medline]
AID - ehu177 [pii]
AID - 10.1093/eurheartj/ehu177 [doi]
PST - ppublish
SO  - Eur Heart J. 2014 Oct 1;35(37):2516-23. doi: 10.1093/eurheartj/ehu177. Epub 2014 
      May 5.